Pravastatin normalizes ET-1-induced contraction in the aorta of type 2 diabetic OLETF rats by suppressing the KSR1/ERK complex

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 303, Issue 7, 2012, Pages

  Nemoto, Shingo ^a   Taguchi, Kumiko ^a   Matsumoto, Takayuki ^a   Kamata, Katsuo ^a   Kobayashi, Tsuneo ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Endothelin 1; Extracellular signal regulated kinase; Kinase suppressor of Ras 1; Mitogen activated protein kinase; Otsuka Long Evans Tokushima fatty rat; Protein phosphatase 2A; Src tyrosine kinase

Indexed keywords

ENDOTHELIN 1; KINASE SUPPRESSOR OF RAS 1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PRAVASTATIN; PROTEIN KINASE P60; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; AORTA MEDIA; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TREATMENT DURATION;

ANIMALS; AORTA, THORACIC; AORTIC DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PRAVASTATIN; PROTEIN KINASES; PROTEIN PHOSPHATASE 2; RATS; RATS, INBRED OLETF; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TIME FACTORS; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 84867146993     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01128.2011     Document Type: Article

References (49)

1. Anselmo AN, Bumeister R, Thomas JM, White MA. Critical contribution of linker proteins to Raf kinase activation. J Biol Chem 277: 5940-5943, 2002.
2. Böhm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res 76: 8-18, 2007.
3. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 106: 1783-1787, 2002.
4. Chen J, Martin BL, Brautigan DL. Regulation of protein serine- threonine phosphatase type-2A by tyrosine phosphorylation. Science 257: 1261-1264, 1992.
5. Chen J, Parsons S, Brautigan DL. Tyrosine phosphorylation of protein phosphatase 2A in response to growth stimulation and v-src transformation of fibroblasts. J Biol Chem 269: 7957-7962, 1994.
6. Donatelli M, Colletti I, Bucalo ML, Russo V, Verga S. Plasma endothelin levels in NIDDM patients with macroangiopathy. Diabetes Res 25: 159-164, 1994.
7. Erpel T, Courtneidge SA. Src family protein tyrosine kinases and cellular signal transduction pathways. Curr Opin Cell Biol 7: 176-182, 1995.
8. Favre B, Turowski P, Hemmings BA. Differential inhibition and post-translational modification of protein phosphatase 1 and 2A in MCF7 cells treated with calyculin-A, okadaic acid, and tautomycin. J Biol Chem 272: 13856-13863, 1997.
9. Hersch E, Huang J, Grider JR, Murthy KS. Gq/G13 signaling by ET-1 in smooth muscle: MYPT1 phosphorylation via ETA and CPI-17 dephosphorylation via ETB. Am J Physiol Cell Physiol 287: C1209-C1218, 2004.
10. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353: 417-439, 2001.
11. Jesmin S, Hattori Y, Maeda S, Zaedi S, Sakuma I, Miyauchi T. Subdepressor dose of benidipine ameliorates diabetic cardiac remodeling accompanied by normalization of upregulated endothelin system in rats. Am J Physiol Heart Circ Physiol 290: H2146-H2154, 2006.
12. Kamata K, Miyata N, Kasuya Y. Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats. Br J Pharmacol 97: 614-618, 1989.
13. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima fatty (OLETF) strain. Diabetes 41: 1422-1428, 1992.
14. Kim B, Kim J, Bae YM, Cho SI, Kwon SC, Jung JY, Park JC, Ahn HY. p38 mitogen-activated protein kinase contributes to the diminished aortic contraction by endothelin-1 in DOCA-salt hypertensive rats. Hypertension 43: 1086-1091, 2004.
15. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113: 1888-1904, 2006.
16. Kobayashi T, Hayashi Y, Taguchi K, Matsumoto T, Kamata K. ANG II enhances contractile responses via PI3-kinase p110 delta pathway in aortas from diabetic rats with systemic hyperinsulinemia. Am J Physiol Heart Circ Physiol 291: H846-H853, 2006.
17. Kobayashi T, Matsumoto T, Kamata K. Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocin-induced diabetic rats. Br J Pharmacol 131: 231-238, 2000.
18. Kobayashi T, Matsumoto T, Ooishi K, Kamata K. Differential expression of 2D-adrenoceptor and eNOS in aortas from early and later stages of diabetes in Goto-Kakizaki rats. Am J Physiol Heart Circ Physiol 287: H135-H143, 2004.
19. Kobayashi T, Miyauchi T, Iwasa S, Sakai S, Fan J, Nagata M, Goto K, Watanabe T. Corresponding distributions of increased endothelin-B receptor expression and increased endothelin-1 expression in the aorta of apolipoprotein E-deficient mice with advanced atherosclerosis. Pathol Int 50: 929-936, 2000.
20. Kobayashi T, Nogami T, Taguchi K, Matsumoto T, Kamata K. Diabetic state, high plasma insulin and angiotensin II combine to augment endothelin-1-induced vasoconstriction via ETA receptors and ERK. Br J Pharmacol 155: 974-983, 2008.
21. Kobayashi T, Taguchi K, Nemoto S, Nogami T, Matsumoto T, Kamata K. Activation of the PDK-1/Akt/eNOS pathway involved in aortic endothelial function differs between hyperinsulinemic and insulin-deficient diabetic rats. Am J Physiol Heart Circ Physiol 297: H1767-H1775, 2009.
22. Kobayashi T, Taguchi K, Yasuhiro T, Matsumoto T, Kamata K. Impairment of PI3-K/Akt pathway underlies attenuated endothelial function in aorta of type 2 diabetic mouse model. Hypertension 44: 956-962, 2004.
23. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Park JB, Shin EK. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 204, 483-490, 2009.
24. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 6: 827-837, 2005.
25. Lee TM, Lin MS, Chou TF, Tsai CH, Chang NC. Effect of pravastatin on development of left ventricular hypertrophy in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289: H220-H227, 2005.
26. Lima VV, Giachini FR, Carneiro FS, Carneiro ZN, Saleh MA, Pollock DM, Fortes ZB, Carvalho MH, Ergul A, Webb RC, Tostes RC. O-GlcNAcylation contributes to augmented vascular reactivity induced by endothelin-1. Hypertension 55: 180-188, 2010.
27. Lin-Lee YC, Pham LV, Tamayo AT, Fu L, Zhou HJ, Yoshimura LC, Decker GL, Ford RJ. Nuclear localization in the biology of the CD40 receptor in normal and neoplastic human B lymphocytes. J Biol Chem 281: 18878-18887, 2006.
28. Li YM, Casida JE. Cantharidin-binding protein: identification as protein phosphatase 2A. Proc Natl Acad Sci USA 89: 11867-11870, 1992.
29. Luttrell DK, Luttrell LM. Not so strange bedfellows: G-protein-coupled receptors and Src family kinases. Oncogene 23: 7969-7978, 2004.
30. Matsumoto T, Ishida K, Nakayama N, Kobayashi T, Kamata K. Involvement of NO and MEK/ERK pathway in enhancement of endothelin-1- induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat. Am J Physiol Heart Circ Physiol 296: H1388-H1397, 2009.
31. Morrison DK. KSR: a MAPK scaffold of the Ras pathway? J Cell Sci 114: 1609-1612, 2001.
32. Nemoto S, Kobayashi T, Taguchi K, Matsumoto T, Kamata K. Losartan improves aortic endothelium-dependent relaxation via prolinerich tyrosine kinase 2/Src/Akt pathway in type 2 diabetic Goto-Kakizaki rats. Am J Physiol Heart Circ Physiol 301: H2383-H2394, 2011.
33. A-receptor expression. Peptides 1: 109-119, 2011.
34. Neylon CB. Vascular biology of endothelin signal transduction. Clin Exp Pharmacol Physiol 26: 149-153, 1999.
35. Oda Y, Renaux B, Bjorge J, Saifeddine M, Fujita DJ, Hollenberg MD. c-Src is a major cytosolic tyrosine kinase in vascular tissue. Can J Physiol Pharmacol 77: 606-617, 1999.
36. Ohmachi M, Rocheleau CE, Church D, Lambie E, Schedl T, Sundaram MV. C. elegans ksr-1 and ksr-2 have both unique and redundant functions and are required for MPK-1 ERK phosphorylation. Curr Biol 12: 427-433, 2002.
37. Ory S, Zhou M, Conrads TP, Veenstra TD, Morrison DK. Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites. Curr Biol 13: 1356-1364, 2003.
38. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22: 153-183, 2001.
39. Pollock DM, Keith TL, Highsmith RF. Endothelin receptors and calcium signaling. FASEB J 9: 1196-1204, 1995.
40. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46: 325-415, 1994.
41. Takahashi M, Ogata Y, Okazaki H, Takeuchi K, Kobayashi E, Ikeda U, Shimada K. Fluvastatin enhances apoptosis in cytokine-stimulated vascular smooth muscle cells. J Cardiovasc Pharmacol 39: 310-317, 2002.
42. Takata M, Urakaze M, Temaru R, Yamazaki K, Nakamura N, Nobata Y, Kishida M, Sato A, Kobayashi M. Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase. Br J Pharmacol 134: 753-762, 2001.
43. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13: 513-609, 1997.
44. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharm Rev 52: 639-672, 2000.
45. Verma S, Arikawa E, McNeill JH. Long-term endothelin receptor blockade improves cardiovascular function in diabetes. Am J Hypertens 14: 679-687, 2001.
46. Verma S, Rao V, Weisel RD, Li SH, Fedak PW, Miriuka S, Li RK. Novel cardioprotective effects of pravastatin in human ventricular cardiomyocytes subjected to hypoxia and reoxygenation: beneficial effects of statins independent of endothelial cells. J Surg Res 119: 66-71, 2004.
47. Yagi K, Kim S, Wanibuchi H, Yamashita T, Yamamura Y, Iwao H. Characteristics of diabetes, blood pressure, and cardiac and renal complications in Otsuka Long-Evans Tokushima fatty rats. Hypertension 29: 728-735. 1997.
48. Yogi A, Callera GE, Montezano AC, Aranha AB, Tostes RC, Schiffrin EL, Touyz RM. Endothelin-1, but not Ang II, activates MAP kinases through c-Src independent Ras-Raf dependent pathways in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 9: 1960-1967, 2007.
49. Yokota T, Utsunomiya K, Murakawa Y, Kurata H, Tajima N. Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy. Kidney Int Suppl 71: S178-S181, 1999.